Literature DB >> 16533759

Isolation of drug delivery from drug effect: problems of optimizing drug delivery parameters.

Mir J Ali1, Yot Navalitloha, Michael W Vavra, Eric W-Y Kang, Andrea C Itskovich, Peter Molnar, Robert M Levy, Dennis R Groothuis.   

Abstract

A recurring question in the treatment of malignant brain tumors has been whether treatment failure is due to inadequate delivery or ineffective drugs. To isolate these issues, we tested a paradigm in which the "therapeutic" agent was a toxin about which there could be no question of efficacy, provided it was delivered in adequate amounts; we used 10% formalin. We infused 10% formalin into 5- to 8-mm subcutaneous RG-2 and D54-MG gliomas at increasing rates until we achieved 100% tumor cell kill. In RG-2 gliomas, infusions of 10 microl/h x 7 days, and 2, 4, 6, and 8 microl/min x 2 h failed to kill tumors, although growth was delayed, while infusion rates of 12 microl/min x 60 min and 48 microl/min x 15 min produced 100% tumor kill. In D54-MG tumors, infusions of 4, 8, and 24 microl/min produced 100% tumor kill. 14C-Formalin autoradiographs showed a heterogeneous distribution after infusions of 2 microl/min x 2 h, whereas infusions of 48 microl/min x 15 min showed a homogeneous distribution within the tumor, but more than 95% of tissue radioactivity was found in tissue surrounding tumor. Drug delivery remains a major issue in brain tumor treatment: Distribution inhomogeneity, rapid efflux, and consequent treatment failures are likely due to high interstitial fluid pressure. Because the infusion rates being used in the treatment of human brain tumors are low and the tumors are larger, treatment failures can be expected on the basis of inadequate drug delivery alone, regardless of the effectiveness of the drug.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16533759      PMCID: PMC1871931          DOI: 10.1215/15228517-2005-007

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  33 in total

Review 1.  Delivery of peptides and proteins through the blood-brain barrier.

Authors:  U Bickel; T Yoshikawa; W M Pardridge
Journal:  Adv Drug Deliv Rev       Date:  2001-03-01       Impact factor: 15.470

2.  Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging.

Authors:  Y Mardor; Y Roth; Z Lidar; T Jonas; R Pfeffer; S E Maier; M Faibel; D Nass; M Hadani; A Orenstein; J S Cohen; Z Ram
Journal:  Cancer Res       Date:  2001-07-01       Impact factor: 12.701

3.  Isogenic transplantation of ethylnitrosourea-induced tumors of the central and peripheral nervous system in two different inbred rat strains.

Authors:  W Wechsler; M A Ramadan; A Gieseler
Journal:  Naturwissenschaften       Date:  1972-10

Review 4.  Clinical cure of glioblastoma--two case reports.

Authors:  T Yoshida; N Kawano; H Oka; K Fujii; Y Nakazato
Journal:  Neurol Med Chir (Tokyo)       Date:  2000-04       Impact factor: 1.742

5.  Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas.

Authors:  C Ryan Miller; Christopher R Williams; Donald J Buchsbaum; G Yancey Gillespie
Journal:  Cancer Res       Date:  2002-02-01       Impact factor: 12.701

Review 6.  DAB389EGF fusion protein therapy of refractory glioblastoma multiforme.

Authors:  Kimberley A Cohen; TieFu Liu; Reid Bissonette; Raj K Puri; Arthur E Frankel
Journal:  Curr Pharm Biotechnol       Date:  2003-02       Impact factor: 2.837

7.  Comparative pharmacokinetics of 14C-sucrose in RG-2 rat gliomas after intravenous and convection-enhanced delivery.

Authors:  Michael Vavra; M Jaffer Ali; Eric W-Y Kang; Yot Navalitloha; Allison Ebert; Cathleen V Allen; Dennis R Groothuis
Journal:  Neuro Oncol       Date:  2004-04       Impact factor: 12.300

8.  Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo.

Authors:  Carlo Giussani; Giorgio Carrabba; Mauro Pluderi; Valeria Lucini; Marilou Pannacci; Dario Caronzolo; Francesco Costa; Matteo Minotti; Giustino Tomei; Roberto Villani; Rona S Carroll; Andreas Bikfalvi; Lorenzo Bello
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

9.  Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma.

Authors:  Ian F Parney; Sandeep Kunwar; Michael McDermott; Mitchel Berger; Michael Prados; Soonmee Cha; David Croteau; Raj K Puri; Susan M Chang
Journal:  J Neurosurg       Date:  2005-02       Impact factor: 5.408

10.  Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme.

Authors:  Geir Olav Hjortland; Solveig Suzanne Garman-Vik; Siri Juell; Oyvind Edon Olsen; Henry Hirschberg; Oystein Fodstad; Olav Engebraaten
Journal:  J Neurosurg       Date:  2004-02       Impact factor: 5.408

View more
  9 in total

Review 1.  Factors influencing the use and interpretation of animal models in the development of parenteral drug delivery systems.

Authors:  Marilyn N Martinez
Journal:  AAPS J       Date:  2011-10-05       Impact factor: 4.009

2.  Therapeutic implications of tumor interstitial fluid pressure in subcutaneous RG-2 tumors.

Authors:  Yot Navalitloha; Erica S Schwartz; Elizabeth N Groothuis; Cathleen V Allen; Robert M Levy; Dennis R Groothuis
Journal:  Neuro Oncol       Date:  2006-06-14       Impact factor: 12.300

3.  Ionizing radiation augments glioma tropism of mesenchymal stem cells.

Authors:  Jonathan G Thomas; Brittany C Parker Kerrigan; Anwar Hossain; Joy Gumin; Naoki Shinojima; Felix Nwajei; Ravesanker Ezhilarasan; Patrice Love; Erik P Sulman; Frederick F Lang
Journal:  J Neurosurg       Date:  2017-03-31       Impact factor: 5.115

Review 4.  Convection-Enhanced Delivery in Children: Techniques and Applications.

Authors:  K Aquilina; A Chakrapani; L Carr; M A Kurian; D Hargrave
Journal:  Adv Tech Stand Neurosurg       Date:  2022

5.  Anatomic compression caused by high-volume convection-enhanced delivery to the brain.

Authors:  Francisco Valles; Massimo S Fiandaca; John Bringas; Peter Dickinson; Richard LeCouteur; Robert Higgins; Mitchel Berger; John Forsayeth; Krystof S Bankiewicz
Journal:  Neurosurgery       Date:  2009-09       Impact factor: 4.654

6.  DNA alkylation products formed by 1-(2-chloroethyl)-1-nitrosourea as molecular dosimeters of therapeutic response.

Authors:  William J Bodell
Journal:  J Neurooncol       Date:  2008-11-02       Impact factor: 4.130

7.  Influence of glioma tumour microenvironment on the transport of ANG1005 via low-density lipoprotein receptor-related protein 1.

Authors:  Y Bertrand; J-C Currie; J Poirier; M Demeule; A Abulrob; D Fatehi; D Stanimirovic; H Sartelet; J-P Castaigne; R Béliveau
Journal:  Br J Cancer       Date:  2011-10-25       Impact factor: 7.640

Review 8.  The use of convection-enhanced delivery with liposomal toxins in neurooncology.

Authors:  Massimo S Fiandaca; Mitchel S Berger; Krystof S Bankiewicz
Journal:  Toxins (Basel)       Date:  2011-03-31       Impact factor: 4.546

Review 9.  Drug-loaded nanoparticle systems and adult stem cells: a potential marriage for the treatment of malignant glioma?

Authors:  Brenda Auffinger; Ramin Morshed; Alex Tobias; Yu Cheng; Atique U Ahmed; Maciej S Lesniak
Journal:  Oncotarget       Date:  2013-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.